Isotopes & Radiation Briefs

摘要

AREVA NP AND BRUCE POWER HAVE SIGNED AN MOU to further explore opportunities to commercialize medical radioisotope production capabilities at the Bruce nuclear power plant in Kincardine, Ontario, Canada. According to Areva, developing on-line production capacity will allow Bruce Power to produce shorter half-life radioisotopes (such as molybdenum-99, lutetium-177, and iridium-192) using a system that inserts and removes targets with little impact on the normal operation of the reactors. Under the memorandum of understanding, signed on August 8, Areva will design and supply the hardware to be installed in the Bruce reactors to add the on-line production capability. According to Areva, the MOU builds on an agreement the company signed with Bruce Power in December 2014 to evaluate the feasibility of developing on-line radioisotope production at Bruce, an eight-unit CANDU pressurized heavy-water reactor plant.